1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1670
  5. Art Unit 1678
  6. Examiner Emch (SPE)

Examiner Emch Gregory S (SPE)

1678-EMCH-GREGORY-S

Employment Information

Art Unit:1678 — Chemistry: molecular biology and microbiology
Group:1670 — Virology, Viral Immunology, And Viral Pathogens, Neurology, Receptors, Cytokines & Recombinant Hormones and Immunoassays and related devices
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
436 — Chemistry: analytical and immunological testing
506 — Combinatorial chemistry technology: method, library, apparatus
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
422 — Chemical apparatus and process disinfecting, deodorizing, preserving, or sterilizing
536 — Organic compounds -- part of the class 532-570 series
Phone:(571) 272-8149
Email:gregory.emch@uspto.gov
Location:VA 22314
Title:Supvy Pat Examnr Biolgy
Service:21 years
Grade:GS-15

Grant Rate and Difficulty Ranking

81
3-Year Grant rate: 49% over 231 cases
Difficulty: Very Hard
Difficulty Percentile: 81st

With Examiner Emch (SPE), you have a 49% chance of getting an issued patent by 3 years after the first office action. Examiner Emch (SPE) is a very hard examiner and in the 81st percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Emch (SPE), where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1678

Examiner Emch (SPE)'s grant rate is lower than that of Art Unit 1678 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Emch (SPE) 1.9
Art Unit 1678 1.9

Interview Benefit

Grant Rate without Interview

Examiner Emch (SPE) has granted 85 of 184 cases without any applicant-requested interviews for a grant rate of 46%.

Grant Rate with Interview

Examiner Emch (SPE) has granted 29 of 47 cases with at least one applicant-requested interview for a grant rate of 62%.

Interview Benefit

With Examiner Emch (SPE), conducting an interview increases your chance of getting a patent granted by 35%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17795216 Method For Predicting Patient Response To Immunotherapy Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
16762273 Targeting Lilrb4 With Car-T Or Car-Nk Cells In The Treatment Of Cancer Patented View
17955743 Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis Abandoned View
17985414 Bead Complex For Detection Of Nucleic Acid Molecules In Biological Samples And Method Of Detecting Nucleic Acid Using The Same Abandoned View
17641342 Bioreceptor Molecules, The Use Of Bioreceptor Molecules, Sensors Containing Electrodes Modified With The Said Bioreceptor Molecules And The Detection Method Of Sars-Cov-2 Virus Abandoned View
17560741 Detection Component For Blood Group Antigens Abandoned View
18007442 Sirpalpha-Fc Fusion Protein Abandoned View
17370514 Method For The Rapid Identification Of Covid-19 Infection Abandoned View
17253436 Diagnostic Assays Using Bacterial Quorum Sensing Signals Abandoned View
17555216 Immunome Wide Association Studies To Identify Condition-Specific Antigens Abandoned View
16462520 Gfap Accumulating In Stroke Patented View
17583602 Inhibitors Of Bcl-2 Patented View
17399971 Antibodies Against Ilt2 And Use Thereof Patented View
17495712 Anti-Dectin-1 Antibodies And Methods Of Use Thereof Patented View
17679841 Detection Of Dystroglycan Abandoned View
17048656 Leukocyte Recruitment In Infectious Disease Abandoned View
17507703 Methods And Systems For Detecting Coronavirus Abandoned View
17295673 Disk Elisa For Quantitative Analysis Abandoned View
17303509 Elevated Temperature Wash For Electrophoresis Abandoned View
16905128 Polypeptides Comprising A Modified Bacteriophage G3p Amino Acid Sequence Lacking A Glycosylation Signal Patented View
17388218 Inhibitors Of Neuroligin 4-Neurexin 1-Beta Protein-Protein Interaction For Treatment Of Liver Disorders Patented View
16956764 Lateral Flow Diagnostic Device Abandoned View
16536090 Cassette Device For Quick Test Of Diagnosis, Method For Detecting A Ligand In A Biological Sample And Kit Abandoned View
15777222 Compositions Comprising Cdnf Or Manf For Use In The Intranasal Treatment Of Central Nervous System Diseases Abandoned View
17697771 Progranulin Variants Patented View
16018447 Oxidized A Beta Peptide Patented View
17156153 Anti-Apoe4 Antigen-Binding Proteins And Methods Of Use Thereof Abandoned View
16392182 Methods Of Diagnosis And Treatment Of Alzheimer's Disease Patented View
16820174 Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds As Modulators Of Neuropeptide Y Receptors Patented View
17182749 Isolation Of Fetal Cells Using Facs Patented View
16349531 Peptides And Antibodies For Detecting Changes In Alzheimer's Disease Brain And Methods Of Use Thereof Patented View
16466713 Antibodies To Human Alpha-Synuclein Abandoned View
15998618 Methodology For Identifying Gene Delivery Vectors With Retinal Cell Specificity In Non-Human Primate Abandoned View
16854717 Compositions And Methods For The Treatment Or Prevention Of Neurodegenerative Disorders Abandoned View
15824273 Use Of Pak4 And Crtc1 For Treatment Or Diagnosis Of Brain Degenerative Disease Abandoned View
16790462 Nano-Theranostics For Parkinson's Disease Patented View
17478592 Rage Fusion Proteins With Improved Stability And Ligand Binding Affinity And Uses Thereof Patented View
16480216 Systems And Methods For Binding Amyloid Fibrils Using Fluorescent Protein Patented View
16626613 Chimeric Antibodies For Treatment Of Amyloid Deposition Diseases Patented View
16500341 System For The Adaptation Of Cell-Based Assays For Analysis On Automated Immuno-Assay Platforms Abandoned View
17073871 Tau Imaging Ligands And Their Uses In The Diagnosis And Treatment Of Tauopathy Patented View
16074166 Mutations That Drive Vh4 Antibody Autoreactivity Patented View
16316278 Use Of Tm9sf1 Gene As Target In Vascular Diseases Abandoned View
16601070 Trem2 Stabilizing Antibodies Patented View
16093363 Treatment Of Ocular Diseases With Fully- Human Post-Translationally Modified Anti-Vegf Fab Abandoned View
16514770 Antibodies And Antigen-Binding Fragments That Specifically Bind To Microtubule-Associated Protein Tau Patented View
16597886 Tuning A Broad Acting Antimicrobial Textile To Act As A Narrow Spectrum Antimicrobial Textile Patented View
16955815 Novel Means And Methods For Treating Neurodegenerative Diseases Abandoned View
15880303 Method Of Identifying Biomarkers Of Neurological Diseases And Diagnosis Of Neurological Diseases Abandoned View
16876702 Method For Achieving Desired Glial Growth Factor 2 Plasma Levels Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.